FibroBiologics - רווח למניה אחת ב-12 החודשים האחרונים FBLG

FibroBiologics, Inc. (FBLG) is managed by cell technology experts who maintain R&D transparency. The scientific team is developing a fibroblast-based regenerative platform to combat chronic pathologies. The YoY TTM change in net income per share illustrates the business growth rate, where 21.70 shows the current value of the metric. The environmental policy is based on strict biosafety controls and the minimization of paper documentation.
FBLG (FibroBiologics Corp): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator calculates the percentage change in the rolling annual earnings per share, determining net yield dynamics to adjust pricing multiples. For FibroBiologics, Inc. (FBLG), whose business is limited to scientific research without commercial products, the current YoY ttm net income per share growth reflects the impact of venture financing and equity issuances on the financial result rather than operational success.